SEC Tracker
Get the app

Karyopharm Therapeutics KPTI

Karyopharm Therapeutics filed for bankruptcy

Item 1.01 Enters material agreement, Item 1.03 Bankruptcy or receivership, Item 2.03 Takes on debt

Form
8-K
Filed
Importance
Major
  1. Filed Chapter 11 bankruptcy on November 2, 2026
  2. Debtors include Karyopharm Therapeutics Inc. and KPT Texas LLC
  3. Restructuring support agreement with 100% of funded debt holders
  4. Prepackaged Chapter 11 plan filed with disclosure statement

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Karyopharm Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

The reading, claim by claim

0 of 3 claims matched the filing text.

Not found in the filing text

  • For the quarter ended June 30, 2026, Karyopharm Therapeutics Inc. reported revenue of $33.4 million and a net income of -$67.0 million.
  • The company's operating margin was -67.4% and net margin was -200.5% for the same period.
  • Revenue decreased by 11.9% compared to the same period a year earlier.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Abvc Biopharma ABVC public float $37M, Jun 30, 2025
  2. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026
  3. Annovis Bio ANVS public float $36M, Jun 30, 2025
  4. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025
  5. Grace Therapeutics GRCE public float $35M, Sep 30, 2025